Pulmonary Surfactant: Synthesis, Regulation, Function, and Clinical Significance

Overview

• Fishman's Pulmonary Diseases and Disorders, p. 122

1. Composition

• Tubular myelin - the most abundant form; a highly organized, square tubular array composed of large, dense aggregates (large aggregate surfactant). This represents the extracellular pool that rapidly moves to the air-liquid interface.
• Lamellar body contents - newly secreted, unraveling to form tubular myelin
• Small aggregate surfactant - less dense, remnant/catabolic forms with poor surface activity, destined for uptake or degradation
• Fishman's Pulmonary Diseases, pp. 122-123

2. Surfactant Proteins (SP-A, SP-B, SP-C, SP-D)

SP-A and SP-D (Hydrophilic collectins)

• Encoded by genes on chromosome 10 (SP-A) and chromosome 19 (SP-D)
• SP-A: Calcium-dependent carbohydrate-binding protein; promotes formation of tubular myelin; modulates alveolar macrophage function; enhances bacterial and viral clearance; regulates surfactant recycling by AT2 cells
• SP-D: Modulates surfactant homeostasis and alveolar immune defense; Sftpd-knockout mice develop severe pulmonary disease with macrophage accumulation confirming its essential role in alveolar homeostasis

SP-B (Hydrophobic)

• Encoded by SFTPB (chromosome 2); 79-amino acid protein
• Stored in lamellar bodies and secreted with phospholipids
• Critical for surfactant film formation and stability - enhances lipid adsorption, aids multilayer formation
• SP-B and SP-C together improve lung inflation, compliance, and are used in exogenous surfactant therapy
• Homozygous loss-of-function mutations → neonatal respiratory failure and death

SP-C (Hydrophobic)

• Encoded by SFTPC (chromosome 8); 35-amino acid hydrophobic peptide; expressed exclusively in AT2 cells
• Palmitoylated on cysteine residues (the palmitoyl groups enhance hydrophobicity and stability of the alpha-helical domain anchoring it in the lipid bilayer)
• Enhances surface-active properties, reduces surface tension during compression, and enhances adsorption rate at the air-water interface
• Dominant mutations in SFTPC → interstitial lung disease in neonates, children, and adults (not RDS alone)
• Fishman's Pulmonary Diseases, pp. 123-125

3. Synthesis and Intracellular Trafficking

The intracellular pathway:

1. Phospholipid synthesis in the endoplasmic reticulum (ER) - DPPC, PG, PC are synthesized
2. Protein synthesis - proSP-B and proSP-C are translated in the ER
3. Golgi processing - proteins traffick through the Golgi apparatus; SP-A and SP-D are secreted via the conventional Golgi pathway
4. Multivesicular body (MVB) - proteins (proSP-B, proSP-C) converge with phospholipids; proteolytic processing to mature peptides begins
5. Lamellar body (LB) formation - the definitive intracellular storage organelle for surfactant; ABCA3 (an ABC transporter) pumps phospholipids (phosphatidylcholine, cholesterol, sphingomyelin, phosphatidylglycerol) into the LB; SP-B and SP-C are stored in the LB; the MVB serves as the integration hub for synthesis, secretion, recycling, and degradation pathways
6. Secretion by exocytosis - LBs fuse with the apical plasma membrane and release contents into the alveolar space
7. Extracellular assembly - in the alveolar hypophase (aqueous lining fluid), SP-A facilitates the transformation of lamellar body material into tubular myelin, which reorganizes into multilayered phospholipid surface films

• Fishman's Pulmonary Diseases, p. 124

4. Regulation of Surfactant Synthesis

A. Developmental/Hormonal Regulation

• Fetal lung surfactant phospholipid content increases markedly with advancing gestational age, driven by a complex signaling/transcriptional network controlling AT2 differentiation
• Glucocorticoids (corticosteroids) are the most potent inducers of lung maturation and surfactant synthesis; they upregulate SP-A, SP-B, SP-C gene expression and accelerate lamellar body development
• Thyroid hormones and beta-adrenergic agents also stimulate surfactant synthesis and secretion
• Glucocorticoid administration to mothers at risk of preterm delivery (<34 weeks) is standard practice to accelerate fetal lung maturation

B. Transcriptional Regulation

• TTF-1/NKX2.1: Master regulator of AT2 cell-specific gene expression (SP-B, SP-C, ABCA3)
• The surfactant protein genes have highly conserved promoter elements responsive to glucocorticoids, thyroid hormones, and other factors

C. Secretion Regulation

• Surfactant secretion by AT2 cells is stimulated by:
  • Beta-adrenergic agonists (catecholamines) - act via cAMP
  • Mechanical stretch (lung inflation/breathing movements)
  • Purinergic signaling (ATP released during stretch)
  • Phorbol esters (PKC activation)
• Secretion is inhibited by: SP-A (negative feedback on secretion), nitrogen mustard

D. Recycling Regulation

• ~50% of secreted surfactant is reuptaken by AT2 cells and repackaged for re-use - a highly efficient recycling system
• SP-D facilitates the reuptake and recycling of small aggregate surfactant
• Alveolar macrophages degrade the rest via lysosomal pathways; GM-CSF (granulocyte-macrophage colony-stimulating factor) is essential for macrophage clearance of surfactant - its deficiency leads to pulmonary alveolar proteinosis (PAP)

E. Fetal Maturity Tests

• Lecithin:Sphingomyelin (L/S) ratio ≥2.0 = lung maturity
• Phosphatidylglycerol appearance in amniotic fluid
• Lamellar body counts
• Fishman's Pulmonary Diseases, p. 124; Murray & Nadel's Respiratory Medicine, p. 81

5. Functions of Pulmonary Surfactant

Primary Function - Surface Tension Reduction

• The phospholipid monolayer at the air-liquid interface lowers surface tension from ~70 dyn/cm² (at a plain air-water interface) to nearly zero at end expiration
• By Laplace's law (P = 2T/r): without surfactant, small alveoli would collapse into large ones; surfactant preferentially reduces tension more at smaller radii, stabilizing alveoli of different sizes
• This prevents atelectasis, reduces the work of breathing, and maintains FRC (functional residual capacity)

Additional Functions

• Fishman's Pulmonary Diseases, p. 2567

6. Clinical Conditions Related to Surfactant

A. Neonatal Respiratory Distress Syndrome (RDS / Hyaline Membrane Disease)

• Cause: Deficiency of surfactant in premature infants (<34-36 weeks); AT2 cells have not yet produced adequate surfactant
• Pathophysiology: Increased alveolar surface tension → alveolar collapse → ventilation-perfusion mismatch → hypoxemia → protein-rich fluid exudate → hyaline membrane formation → respiratory failure
• Prevention: Antenatal glucocorticoids to mother (betamethasone/dexamethasone) given 24-48h before preterm delivery
• Treatment: Exogenous surfactant replacement (intratracheal instillation via endotracheal tube); newer delivery methods include nebulization and thin-catheter instillation during nasal CPAP (INSURE technique)
• Surfactant therapy reduces RDS mortality by 30-40% and reduces morbidity from pneumothorax, pulmonary interstitial emphysema, bronchopulmonary dysplasia (BPD), and intraventricular hemorrhage
• Natural surfactants (from bovine or porcine lung lavage) are superior to original synthetic surfactants; newer-generation synthetic surfactants with peptide analogues of SP-B and SP-C are in clinical trials

B. Acute Respiratory Distress Syndrome (ARDS)

• Plasma proteins that leak into alveoli during ARDS inactivate surfactant - fibrinogen, albumin, and lipids from inflammatory cells competitively displace surfactant from the air-liquid interface
• Surfactant therapy in ARDS is under investigation; recent 2025 meta-analysis (PMID 40399976) in children shows potential benefit in reducing mechanical ventilation duration

C. Meconium Aspiration Syndrome

• Meconium inactivates surfactant
• Exogenous surfactant reduces the need for mechanical ventilation and ECMO, and reduces hospital stay

D. Genetic Surfactant Dysfunction Disorders

• Murray & Nadel's Respiratory Medicine, pp. 541-555

E. Pulmonary Alveolar Proteinosis (PAP)

• Accumulation of surfactant lipids and proteins in alveoli due to defective clearance by macrophages
• Autoimmune PAP: anti-GM-CSF antibodies block macrophage maturation (most common form)
• Congenital PAP: mutations in GM-CSF receptor (CSF2RA, CSF2RB) or SP genes
• Treatment: whole-lung lavage; GM-CSF inhaled or subcutaneous (for autoimmune PAP)

F. Exogenous Surfactant Preparations

Summary

• Fishman's Pulmonary Diseases and Disorders, 2-Volume Set, Chapter 5 (Surfactant Composition, Synthesis, and Metabolism), pp. 122-125
• Murray & Nadel's Textbook of Respiratory Medicine, 2-Volume, Chapter 3 (Functional Roles of the Alveolar Unit), pp. 81-82; Chapter 23 (Surfactant Metabolic Dysfunction Disorders), pp. 541-555
• Fishman's Pulmonary Diseases, p. 2567 (Pulmonary Surfactant Clinical Use)
• Recent evidence: Surfactant + budesonide in premature infants (PMID 39787118) - 2025 meta-analysis; Surfactant therapy in pediatric ARDS (PMID 40399976) - 2025 meta-analysis

Hamburger Phenomenon (Chloride Shift) and the Haldane Effect

Part 1: The Hamburger Phenomenon (Chloride Shift)

Definition

Mechanism - At the Tissue Capillaries

1. CO₂ diffuses from tissue cells into plasma, then into RBCs (dissolved CO₂ = ~7% of total transport)
2. Inside the RBC, CO₂ + H₂O → H₂CO₃ (catalyzed by carbonic anhydrase, ~5000× faster than in plasma - this is why the reaction is physiologically meaningful)
3. H₂CO₃ rapidly dissociates: H₂CO₃ → H⁺ + HCO₃⁻
4. The H⁺ ions are buffered by hemoglobin (histidine residues of Hb act as a buffer, absorbing H⁺): HbO₂ + H⁺ → HbH⁺ + O₂
5. HCO₃⁻ accumulates inside the RBC and diffuses out into plasma down its concentration gradient - this is the major form of CO₂ transport (~70% of total CO₂)
6. To maintain electrical neutrality (since HCO₃⁻ is leaving the cell), Cl⁻ ions move from plasma INTO the RBC via a specific bicarbonate-chloride anion exchanger (Band 3 protein / AE1) in the RBC membrane - this is the Hamburger / chloride shift

Result: Venous RBCs have a higher Cl⁻ content than arterial RBCs. Venous blood plasma has a higher HCO₃⁻ content than arterial plasma.

Reversal - At the Pulmonary Capillaries

1. PO₂ rises (from ~40 to ~100 mmHg) → O₂ binds hemoglobin (HbH⁺ + O₂ → HbO₂ + H⁺)
2. Released H⁺ combines with HCO₃⁻: H⁺ + HCO₃⁻ → H₂CO₃ → CO₂ + H₂O
3. CO₂ is released and diffuses into the alveolus
4. As HCO₃⁻ is consumed, more HCO₃⁻ re-enters the RBC from plasma
5. Cl⁻ exits the RBC back into plasma to maintain electrical neutrality (reverse chloride shift)

Result: Cl⁻ content of arterial RBCs is lower than venous RBCs. CO₂ is expelled from the lungs.

Key Facts Summary

• Carbonic anhydrase inhibitors (e.g., acetazolamide) block this reaction, significantly impairing CO₂ transport - tissue PCO₂ can rise from 45 to ~80 mmHg
• The chloride shift causes a slight increase in venous RBC volume (as Cl⁻ entry draws water in osmotically) - this slightly increases venous hematocrit (the "venous hematocrit effect")
• Guyton & Hall Medical Physiology, p. 529; Morgan & Mikhail's Clinical Anesthesiology, p. 967

Part 2: The Haldane Effect

Definition

Guyton & Hall notes: "The Haldane effect is quantitatively far more important in promoting CO₂ transport than the Bohr effect is in promoting O₂ transport."

The CO₂ Dissociation Curve - Graphic Explanation

Mechanism of the Haldane Effect

Mechanism 1: Oxylabile Carbamate (Carbaminohemoglobin)

• CO₂ binds to N-terminal amino groups of hemoglobin to form carbaminohemoglobin (Hb-CO₂): R-NH₂ + CO₂ → R-NHCOO⁻ + H⁺
• Deoxyhemoglobin has 3.5× greater affinity for CO₂ than oxyhemoglobin (due to changes in quaternary structure upon deoxygenation that make N-terminal amino groups more available for carbamate formation)
• In tissues: O₂ is released → hemoglobin becomes deoxyhemoglobin → binds more CO₂ as carbamate
• In lungs: O₂ binds → hemoglobin becomes oxyhemoglobin → becomes a stronger acid → less tendency to form carbaminohemoglobin → CO₂ released

This carbamate mechanism accounts for approximately 1/8 of the arterio-venous CO₂ difference (its physiological importance would be twice as great, but is reduced by competition with 2,3-DPG for the same N-terminal amino groups)

Mechanism 2: Oxylabile Buffering (Bicarbonate Pathway)

• The pKa of hemoglobin changes with its oxygenation state
• Deoxyhemoglobin is a stronger base (weaker acid) than oxyhemoglobin
• In tissues: Hb deoxygenates → becomes better at buffering H⁺ → this H⁺ buffering drives the reaction CO₂ + H₂O → H₂CO₃ → H⁺ + HCO₃⁻ further to the right → more CO₂ stored as bicarbonate
  • Reaction: CO₂ + H₂O + HbO₂ → HbH⁺ + HCO₃⁻ + O₂
• In lungs: O₂ binds Hb → Hb becomes oxyhemoglobin → weaker base → releases H⁺ → H⁺ + HCO₃⁻ → H₂CO₃ → CO₂ released

Both mechanisms together account for the full Haldane effect. Approximately equal contributions come from oxylabile carbamate and oxylabile buffering (bicarbonate formation).

Quantitative Significance

• Fishman's Pulmonary Diseases, pp. 258-259; Guyton & Hall, p. 530

Comparing the Two Phenomena

Relationship to the Bohr Effect

Clinical Relevance

• Guyton & Hall Textbook of Medical Physiology, pp. 529-530
• Fishman's Pulmonary Diseases and Disorders, pp. 258-259 (Haldane Effect)
• Morgan & Mikhail's Clinical Anesthesiology, 7e, pp. 967-968 (Chloride/Hamburger shift; Haldane effect)
• Murray & Nadel's Textbook of Respiratory Medicine, p. 82 (CO₂ transport and Haldane effect)